PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Open-label Extension Study Of RN624

Phase 2

Completed

Conditions: Osteoarthritis
OA Knee Pain
Arthritis

Interventions: Drug: RN624 (PF-04383119)

First Posted Date: 2006-11-15

Last Posted Date: 2021-02-02

Lead Sponsor: Pfizer

Target Recruit Count: 287

Registration Number: NCT00399490

Locations: 🇺🇸
Sports Medicine and Orthopaedics Center, Greensboro, North Carolina, United States
🇺🇸
Office of Walter F. Chase, MD, PA, Austin, Texas, United States
🇺🇸
Northwest Indiana Center for Clinical Research, Merrillville, Indiana, United States

and more 33 locations

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Phase 3

Terminated

Conditions: Obesity

Interventions: Drug: CP-945,598 Treatment B
Drug: CP-945,598 Treatment A
Drug: Placebo

First Posted Date: 2006-11-07

Last Posted Date: 2012-11-07

Lead Sponsor: Pfizer

Target Recruit Count: 1253

Registration Number: NCT00396448

Locations: 🇬🇧
Pfizer Investigational Site, Northwood, Middlesex, United Kingdom

Safety Study In Patients Who Were Born Small And Short And Were Treated With Growth Hormone To Achieve Normal Height

Withdrawn

Conditions: Infant, Small for Gestational Age

Interventions: Other: post GH treatment observational study

First Posted Date: 2006-11-07

Last Posted Date: 2015-04-22

Lead Sponsor: Pfizer

Registration Number: NCT00396474

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

Phase 3

Completed

Conditions: Idiopathic Short Stature

Interventions: Drug: Genotropin

First Posted Date: 2006-11-06

Last Posted Date: 2016-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 316

Registration Number: NCT00396097

Locations: 🇺🇸
Central Ohio Pediatric Endocrinology/Diabetes Services (COPEDS), Columbus, Ohio, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Cooks Children Medical Center/Dept. of Pediatric Endocrinology, Fort Worth, Texas, United States

and more 39 locations

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: placebo
Drug: RN624 (PF-04383119)

First Posted Date: 2006-11-01

Last Posted Date: 2009-10-12

Lead Sponsor: Pfizer

Target Recruit Count: 450

Registration Number: NCT00394563

Locations: 🇺🇸
Pfizer Investigational Site, Yakima, Washington, United States

Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Taxotere
Drug: Sunitinib malate

First Posted Date: 2006-10-31

Last Posted Date: 2012-07-19

Lead Sponsor: Pfizer

Target Recruit Count: 594

Registration Number: NCT00393939

Locations: 🇬🇧
Pfizer Investigational Site, Wolverhampton, United Kingdom

A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis

Phase 3

Completed

Conditions: Upper Respiratory Tract Infection

First Posted Date: 2006-10-29

Last Posted Date: 2008-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 99

Registration Number: NCT00393835

Locations: 🇯🇵
Pfizer Investigational Site, Wakayama, Japan

Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne

Phase 3

Terminated

Conditions: Acne Vulgaris

Interventions: Drug: Azithromycin microspheres
Drug: Azithromycin microspheres-placebo
Drug: Minocycline capsules,
Drug: minocycline-placebo capsules

First Posted Date: 2006-10-25

Last Posted Date: 2010-01-12

Lead Sponsor: Pfizer

Target Recruit Count: 118

Registration Number: NCT00392223

Locations: 🇮🇹
Pfizer Investigational Site, Trieste, Italy

A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers

Phase 1

Completed

Conditions: Osteoarthritis

Interventions: Drug: placebo
Drug: CJ-023,423
Drug: naproxen

First Posted Date: 2006-10-25

Last Posted Date: 2008-03-24

Lead Sponsor: Pfizer

Target Recruit Count: 340

Registration Number: NCT00392080

Locations: 🇺🇸
Pfizer Investigational Site, Chesapeake, Virginia, United States

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

Phase 3

Terminated

Conditions: Obesity

Interventions: Drug: Placebo
Drug: CP-945,598
Drug: CP-945,598 Treatment B

First Posted Date: 2006-10-23

Last Posted Date: 2012-11-07

Lead Sponsor: Pfizer

Target Recruit Count: 975

Registration Number: NCT00391196

Locations: 🇬🇧
Pfizer Investigational Site, Luton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy